Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 4.88 USD -9.12% Market Closed
Market Cap: $33m

Cingulate Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cingulate Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Cingulate Inc
NASDAQ:CING
Research & Development
-$9.4m
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Research & Development
-$14.7B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.7B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.1B
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Research & Development
-$15.5B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$12.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
No Stocks Found

Cingulate Inc
Glance View

Market Cap
33m USD
Industry
Pharmaceuticals

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

CING Intrinsic Value
4.98 USD
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Cingulate Inc's Research & Development?
Research & Development
-9.4m USD

Based on the financial report for Dec 31, 2024, Cingulate Inc's Research & Development amounts to -9.4m USD.

What is Cingulate Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-1%

Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for Cingulate Inc have been -4% over the past three years , -1% over the past five years .

Back to Top